BioSpace News Archive

Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, announced today that the first participants have been dosed in a Phase II open-label trial of AKS-452, its protein subunit COVID-19 vaccine candidate.

Breckenridge Pharmaceutical, Inc. announces today that the U.S. Food and Drug Administration has granted final approval of its Abbreviated New Drug Application for Apixaban Tablets (generic for Eliquis®).

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today reported recent business progress and financial results for the second quarter, June 30, 2021.

Arcutis Biotherapeutics, Inc., a late-stage biopharmaceutical company focused on developing meaningful innovations to address the urgent needs of patients living with immune-mediated dermatological diseases and conditions, or immuno-dermatology, reported financial results for the quarter ended June 30, 2021, and provided a business update.

Calithera Biosciences, Inc. (Nasdaq: CALA), a fully-integrated clinical stage biotechnology company focused on discovering and developing novel, small molecule drugs for the treatment of cancer and other life-threatening diseases, announced today its financial results for the second quarter ended June 30, 2021.

Expanded pervasiveness of persistent infections, flood in geriatric populace, and progressions in innovation drive the development of the worldwide home medical equipment market.

Increase in geriatric population, rise in prevalence of arthritis, high demand from athletes, and lesser side effects as compared to conventional oral medicines would facilitate the growth of the global topical pain relief market.

The global protein therapeutics market was valued at $140,109 million in 2016, and is projected to reach $217,591 million by 2023, growing at a CAGR of 6.5% from 2017 to 2023.

Oxurion NV, a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a clinical stage portfolio in vascular retinal disorders, announces its management will participate and meet with investors at the following upcoming virtual meetings

The Biotechnology Institute reported on the success of its signature program, the 2021 International BioGENEius Challenge and that of its newest venture, BioDiversity 2021, both in partnership with Johnson & Johnson.